// App-Quantinova.ai

P113 : Reduction Of Risk Of Secondary Progressive Multiple Sclerosis Within Two Years Of Treatment With Cladribine Tablets: An Analysis Of The CLARITY Study

Researchers

Presenter

  • P. Vermersch

Principal Investigators

  • G. Giovannoni

  • P. Soelberg-Srensen

  • K. Rammohan

  • S. Cook

  • B. Keller

  • S. Roy

Medical Centers

  • Universite de Lille 3, Lille, France

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

  • Department of Neurology, Danish Headache Center; University of Copenhagen Copenhagen Denmark

  • Multiple Sclerosis Center, University of Miami, Miami, FL

  • Rutgers-New Jersey Medical School, Newark, NJ

  • Merck KGaA, Darmstadt, Germany

  • Merck KGaA, Aubonne, Switzerland

Locations

  • France

  • United Kingdom

  • Denmark

  • United States

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved